{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:02:01Z","timestamp":1784808121178,"version":"3.55.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Radiotherapy is a primary treatment modality for patients with brain metastases (BMs). However, individualized prediction of overall survival (OS) in this patient cohort remains a considerable clinical challenge. This study aimed to develop a prognostic model for estimating OS in patients with BMs receiving radiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted, enrolling 298 patients with radiologically confirmed BMs who received radiotherapy from January 2020 to December 2021. Least absolute shrinkage and selection operator (LASSO) Cox regression was used to identify key prognostic factors for OS. A nomogram was developed based on multivariate Cox regression models to predict 1-, 2-, and 3-year OS. The nomogram\u2019s performance was assessed using time-dependent receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA). A random survival forest (RSF) model was additionally used to evaluate the relative importance of each prognostic predictor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      LASSO regression identified six key prognostic variables: sex, primary tumor type, graded prognostic assessment (GPA) class, targeted\/immunotherapy administration, primary tumor control status, and post-radiotherapy systemic therapy. All six variables were independently associated with OS. The nomogram showed moderate discriminative ability, with area under the curve (AUC) values of 0.773, 0.763, and 0.723 for 1-, 2-, and 3-year OS, respectively. Calibration plots showed reasonable agreement between predicted and observed OS outcomes. DCA suggested potential clinical net benefit across the assessed threshold probabilities. Using a total score cutoff of 224, patients were stratified into high-risk and low-risk groups, with significantly different OS between the two groups (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). RSF analysis indicated that sex and primary tumor type were the most informative predictors of OS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The developed prognostic nomogram integrates readily available clinical and treatment-related characteristics to estimate OS in radiotherapy-treated patients with BMs. This model may assist individualized risk stratification and clinical decision-making, although further external validation is needed. An interactive dynamic nomogram is accessible online at:\n                      <jats:ext-link>https:\/\/mengdie710.shinyapps.io\/DynNomapp\/<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1834582","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:10:19Z","timestamp":1784805019000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a nomogram for overall survival risk stratification in patients with brain metastases undergoing radiotherapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Mengdie","family":"Zhao","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Bengbu Medical University, Bengbu","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqun","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Bengbu Medical University, Bengbu","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhong","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Bengbu Medical University, Bengbu","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianwen","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Bengbu Medical University, Bengbu","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Li","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Bengbu Medical University, Bengbu","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwen","family":"Guo","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Wannan Medical College, Wuhu","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifei","family":"Huang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Bengbu Medical University, Bengbu","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Li","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Bengbu Medical University, Bengbu","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","article-title":"Brain metastases.","volume":"5","author":"Achrol","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nrclinonc.2011.58","article-title":"The biology of brain metastases-translation to new therapies.","volume":"8","author":"Eichler","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study.","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12890-023-02312-y","article-title":"Factors for incidence risk and prognosis of synchronous brain metastases in pulmonary large cell carcinoma patients: a population-based study.","volume":"23","author":"Zheng","year":"2023","journal-title":"BMC Pulm Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cam4.4978","article-title":"Predictive value of clinical characteristics on risk and prognosis of synchronous brain metastases in small-cell lung cancer patients: a population-based study.","volume":"12","author":"Zhou","year":"2023","journal-title":"Cancer Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1200\/JCO.2006.09.9861","article-title":"Chemotherapy delivery issues in central nervous system malignancy: a reality check.","volume":"25","author":"Muldoon","year":"2007","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1200\/JCO.2011.41.0639","article-title":"A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results.","volume":"31","author":"Soffietti","year":"2013","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/s43018-023-00585-0","article-title":"Leveraging translational insights toward precision medicine approaches for brain metastases.","volume":"4","author":"Kim","year":"2023","journal-title":"Nat Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1002\/cncr.26515","article-title":"A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases.","volume":"118","author":"Tsao","year":"2012","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for brain metastases: ASCO-SNO-ASTRO guideline.","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.prro.2022.02.003","article-title":"Radiation therapy for brain metastases: an ASTRO clinical practice guideline.","volume":"12","author":"Gondi","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/s0360-3016(96)00619-0","article-title":"Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.","volume":"37","author":"Gaspar","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B14","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ijrobp.2007.06.074","article-title":"A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database.","volume":"70","author":"Sperduto","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1200\/JCO.20.01255","article-title":"Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient.","volume":"38","author":"Sperduto","year":"2020","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1093\/neuonc\/nos087","article-title":"A nomogram for individualized estimation of survival among patients with brain metastasis.","volume":"14","author":"Barnholtz-Sloan","year":"2012","journal-title":"Neuro Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"10732748241255212","DOI":"10.1177\/10732748241255212","article-title":"Survival predictive nomograms for non-surgical brain metastases patients from non-small cell lung cancer receiving radiotherapy: a population-based study.","volume":"31","author":"Li","year":"2024","journal-title":"Cancer Control"},{"key":"B18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.clineuro.2016.02.022","article-title":"Predicted survival in patients with brain metastases from colorectal cancer: is a current nomogram helpful?","volume":"143","author":"Nieder","year":"2016","journal-title":"Clin Neurol Neurosurg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.7150\/jca.18600","article-title":"Short survival time after palliative whole brain radiotherapy: can we predict potential overtreatment by use of a nomogram?","volume":"8","author":"Nieder","year":"2017","journal-title":"J Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"610691","DOI":"10.3389\/fonc.2020.610691","article-title":"Computer tomography radiomics-based nomogram in the survival prediction for brain metastases from non-small cell lung cancer underwent whole brain radiotherapy.","volume":"10","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"659538","DOI":"10.3389\/fonc.2021.659538","article-title":"Individualized nomogram for predicting survival in patients with brain metastases after stereotactic radiosurgery utilizing driver gene mutations and volumetric surrogates.","volume":"11","author":"Zhou","year":"2021","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/aje\/kwk052","article-title":"Relaxing the rule of ten events per variable in logistic and Cox regression.","volume":"165","author":"Vittinghoff","year":"2007","journal-title":"Am J Epidemiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jclinepi.2016.02.031","article-title":"Adequate sample size for developing prediction models is not simply related to events per variable.","volume":"76","author":"Ogundimu","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1002\/sim.7992","article-title":"Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes.","volume":"38","author":"Riley","year":"2019","journal-title":"Stat Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13014-022-02096-1","article-title":"Retrospective study of hypofractionated stereotactic radiotherapy combined with whole brain radiotherapy for patients with brain metastases.","volume":"17","author":"Xie","year":"2022","journal-title":"Radiat Oncol"},{"key":"B26","first-page":"i","article-title":"Obesity: preventing and managing the global epidemic. Report of a WHO consultation.","volume":"894","year":"2000","journal-title":"World Health Organ Tech Rep Ser."},{"key":"B27","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L","article-title":"The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma.","volume":"1","author":"Karnofsky","year":"1948","journal-title":"Cancer."},{"key":"B28","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s10585-023-10237-3","article-title":"Development and adaptations of the Graded Prognostic Assessment (GPA) scale: a systematic review.","volume":"40","author":"Ribeiro","year":"2023","journal-title":"Clin Exp Metastasis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/s0360-3016(99)00549-0","article-title":"Radiosurgery for brain metastases: a score index for predicting prognosis.","volume":"46","author":"Weltman","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2018.03.018","article-title":"Prognostic and predictive factors in patients with brain metastases from solid tumors: a review of published nomograms.","volume":"126","author":"Nieder","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1093\/neuonc\/nou018","article-title":"A nomogram for predicting distant brain failure in patients treated with gamma knife stereotactic radiosurgery without whole brain radiotherapy.","volume":"16","author":"Ayala-Peacock","year":"2014","journal-title":"Neuro Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1002\/cncr.29590","article-title":"Novel risk stratification score for predicting early distant brain failure and salvage whole-brain radiotherapy after stereotactic radiosurgery for brain metastases.","volume":"121","author":"Press","year":"2015","journal-title":"Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ijrobp.2016.09.043","article-title":"Multi-institutional nomogram predicting survival free from salvage whole brain radiation after radiosurgery in patients with brain metastases.","volume":"97","author":"Gorovets","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.clineuro.2018.11.011","article-title":"Analysis of the drivers of cost of management when patients with brain metastases are treated with upfront radiosurgery.","volume":"176","author":"Shenker","year":"2019","journal-title":"Clin Neurol Neurosurg"},{"key":"B35","doi-asserted-by":"publisher","first-page":"8639","DOI":"10.1038\/s41598-021-88070-5","article-title":"Hypofractionated and single-fraction radiosurgery for brain metastases with sex as a key predictor of overall survival.","volume":"11","author":"Mangesius","year":"2021","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ejca.2022.11.012","article-title":"Immunotherapy for brain metastases and primary brain tumors.","volume":"179","author":"Di Giacomo","year":"2023","journal-title":"Eur J Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1111\/1759-7714.14473","article-title":"An integrated biomarker of PD-L1 expression and intraepithelial CD8+ T cell infiltration was associated with the prognosis of lung cancer patients after intracranial resection of brain metastases.","volume":"13","author":"Li","year":"2022","journal-title":"Thorac Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13058-015-0665-1","article-title":"Breast cancer brain metastases: biology and new clinical perspectives.","volume":"18","author":"Witzel","year":"2016","journal-title":"Breast Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"111705","DOI":"10.1016\/j.intimp.2024.111705","article-title":"G-CSF improving combined whole brain radiotherapy and immunotherapy prognosis of non-small cell lung cancer brain metastases.","volume":"130","author":"Luo","year":"2024","journal-title":"Int Immunopharmacol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1834582\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:10:20Z","timestamp":1784805020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1834582\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":39,"alternative-id":["10.3389\/fmed.2026.1834582"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1834582","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"article-number":"1834582"}}